{
    "name": "tranexamic acid injection",
    "comment": "Rx",
    "other_names": [
        "Cyklokapron"
    ],
    "classes": [
        "Antifibrinolytic Agents"
    ],
    "source": "https://reference.medscape.com/drug/cyklokapron-tranexamic-acid-injection-342087",
    "pregnancy": {
        "common": [
            "Available data from published studies, case series and case reports with tranexamic acid use in pregnant women in second and third trimester and at time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes",
            "There are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear",
            "Drug is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Reproduction studies performed in mice, rats, and rabbits have not revealed any adverse effects on fetus due to tranexamic acid administered during organogenesis; doses examined were multiples of up to 3 times (mouse), 6 times (rat), and 3 times (rabbit) maximum human dose based on body surface area in the mouse, rat, and rabbit, respectively"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Concomitant use of drug, which is an antifibrinolytic, with hormonal contraceptives may increase risk for thromboembolic adverse reactions; advise patients to use an effective alternative (nonhormonal) contraceptive method"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Published literature reports presence of tranexamic acid in human milk; there are no data on effects of drug on breastfed child or effects on milk production; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for drug and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Acquired defective color vision",
                "Subarachnoid hemorrhage",
                "Active intravascular clotting"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in renal impairment, subarachnoid hemorrhage, vascular disease, thromboembolic history, and DIC",
                "Ureteral obstruction resulting from clot formation reported; use caution in patients with upper urinary tract bleeding",
                "Thromboembolism or venous and arterial thrombosis reported",
                "Ligneous conjunctivitis has been reported",
                "Concurrent use with anti-inhibitor coagulant complex/factor IX complex concentrates may further increase risk of thrombosis",
                "Concurrent use with tretinoin may exacerbate procoagulant effects",
                "Anaphylaxis reported with intravenous administration",
                "For intravenous use only; serious adverse reactions including seizures and cardiac arrythmias have occurred when drug inadvertently administered intrathecally instead of intravenously; confirm correct route of administration and avoid confusion with other injectable solutions that might be administered at same time as the drug; syringes containing drug should be clearly labeled with intravenous route of administration"
            ],
            "specific": [
                {
                    "type": "Visual disturbances",
                    "description": [
                        "Visual defects (color vision change or visual loss) reported",
                        "In addition, although not seen in humans, focal areas of retinal degeneration have been observed in cats and dogs following oral or intravenous tranexamic acid at doses between 250 to 1600 mg/kg/day (1.6 to 22 times recommended usual human dose based on body surface area) from 6 days to 1 year",
                        "No retinal changes observed in eye examinations of patients treated with tranexamic acid for up to 8 years; patients expected to be treated for greater than 3 months may consider ophthalmic monitoring including visual acuity and optical coherence tomography at regular intervals; discontinue tranexamic acid in sodium chloride injection if changes in ophthalmological examination occur"
                    ]
                },
                {
                    "type": "Seizures",
                    "description": [
                        "May cause seizures, including focal and generalized seizures; the most common setting for tranexamic acid-induced seizures has been during cardiovascular surgery (a setting in which drug is not FDA approved and which uses doses of up to ten-fold higher than recommended human dose and in patients inadvertently given tranexamic acid into the neuraxial system)",
                        "Consider dose reduction during surgery and dose adjustments for patients with clinical conditions such as renal dysfunction; closely monitor patient during surgery",
                        "Consider electroencephalogram (EEG) monitoring for patients with history of seizures or who experience myoclonic movements, twitching, or show evidence of focal seizures; discontinue drug if seizures occur"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "prothrombin complex concentrate, human",
            "description": {
                "common": "tranexamic acid injection increases effects of prothrombin complex concentrate, human by pharmacodynamic synergism. Contraindicated. Coadministration increases risk of thrombosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anti-inhibitor coagulant complex",
            "description": {
                "common": "anti-inhibitor coagulant complex, tranexamic acid injection.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration ma."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Factor IX",
            "description": {
                "common": "tranexamic acid injection increases effects of Factor IX by pharmacodynamic synergism. Contraindicated. Risk of thrombosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Factor IX, recombinant",
            "description": {
                "common": "tranexamic acid injection increases effects of Factor IX, recombinant by pharmacodynamic synergism. Contraindicated. Risk of thrombosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "defibrotide",
            "description": {
                "common": "tranexamic acid injection decreases effects of defibrotide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Defibrotide may diminish effects of thrombolytic agents. Consider therapy modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mestranol",
            "description": {
                "common": "tranexamic acid injection, mestranol.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of thromboembolic disorder."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Visual abnormalities",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "with rapid injection",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        }
    ]
}